AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

“Without a commercial arrangement that results in a price that represents a cost-effective use of NHS resources, NICE cannot recommend Enhertu." Vertex's gene-editing therapy for sickle cell ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

London stocks were set to nudge lower at the open on Tuesday following heavy losses on the S&P 500 and the Nasdaq.

US drug prices have soared over the last several decades ... now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

RHHBY (OTC:RHHBY)), a pharmaceutical giant with a market capitalization of $265.76 billion, saw its price target increased by Deutsche Bank (ETR:DBKGn) from CHF250.00 to CHF265.00, while the firm ...

PHARMACEUTICAL giant AstraZeneca has scrapped plans for a £450m (US$559m) upgrade to its vaccine manufacturing facility in ...

Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...